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Abstract
Background: The potential cardioprotective benefits of olive oil (OO) and canola oil (CO) consumption have been
shown in some studies. The present study compared the effects of CO and OO on plasma lipids, some
inflammatory cytokines, and lipoprotein-associated phospholipase A2 (Lp-PLA2) mass and activity in patients
undergoing coronary angiography.
Methods: The current randomized, controlled, parallel-arm, clinical trial involved 48 patients (44 men and 4 women,
aged 57.63 ± 6.34 years) with at least one classic cardiovascular risk factor (hypertension, dyslipidemia, or diabetes)
who referred for coronary angiography. Patients were randomly divided into two groups and received 25 mL/day
refined olive oil (n = 24) or canola oil (n = 24) for 6 weeks. Plasma lipids, some selected inflammatory markers, and
Lp-PLA2 levels were measured at baseline and after the intervention.
Results: CO consumption produced a significant reduction in plasma Lp-PLA2 mass (− 0.97 ± 1.84 vs. 0.34 ± 1.57 ng/
mL, p = 0.008 for CO and OO, respectively), whereas the mean changes in interleukine-6 concentration were
significantly lower after OO consumption compared with CO (− 9.46 ± 9.46 vs. -0.90 ± 6.80 pg/mL, p = 0.008 for OO
and CO, respectively). After 6 weeks of intervention, no significant changes were observed in plasma Lp-PLA2
activity, complement C3, C4, or lipid profiles in the two intervention groups.
Conclusions: Comparing the two vegetable oils in subjects with cardiovascular risk factors showed that the
consumption of olive oil is more effective in reducing the level of inflammatory cytokine interleukine-6, whereas
canola oil was more effective in lowering Lp-PLA2 levels; however, this finding should be interpreted with caution,
because Lp-PLA2 activity did not change significantly.
Trial registration: IRCT20160702028742N5 at www.irct.ir (04/19/2019).
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Background
Lifestyle modification, including a healthy diet, is the
first therapeutic step to reducing cardiovascular disease
(CVD) [1]. Reducing the amount of dietary saturated
fatty acids (SFAs) and replacing them with unsaturated
fats are among the main nutritional recommendations
for the prevention and treatment of CVD [2]. Inclusion
of vegetable oils rich in monounsaturated fatty acids
(MUFAs) in the diet has been associated with several
cardioprotective effects [3]. Olive and canola oils, two
commonly consumed vegetable oils, are low in SFAs but
rich in MUFAs, and both are recommended to be in-
cluded in a healthy diet for cardioprotection [4, 5].
The potential cardioprotective benefits of olive oil
(OO) consumption, especially in the Mediterranean diet,
have been extensively studied [4, 6]. Scientific evidence
suggests, however, that replacing SFAs with polyunsatur-
ated fatty acids (PUFAs) may reduce CVD risk factors
somewhat more than replacing SFAs with MUFAs [2].
In addition to their beneficial effects, PUFAs have been
shown to be safe [7]. Therefore, oils with low SFAs that
contain relatively high levels of PUFAs as well as
MUFAs may be preferable for improving cardiovascular
risk factors. Canola oil (CO) which contains low
amounts of SFAs, high amounts of MUFAs, and rela-
tively high amounts of PUFAs could be a reasonable
choice for inclusion in a healthy diet to replace SFAs
and increase unsaturated fats intake [8]. Evidence sup-
ports several potential health benefits of canola oil con-
sumption in terms of reducing cardiovascular risk
factors and improving health [5]. The comparison of
canola and olive oils showed that the MUFA content of
OO is slightly higher, while the amount of PUFAs is
higher in CO [5].
In addition to the classic CVD risk factors such as
plasma lipid and lipoprotein concentrations, measuring
inflammatory biomarkers is useful for cardiovascular risk
assessment and predicting cardiovascular risk [9, 10].
Numerous inflammatory biomarkers are implicated in
atherosclerosis; each one increases our understanding of
this complex process. Interleukin-6 (IL-6) is among the
well-studied inflammatory biomarkers related to cardio-
vascular risk [10–13]. Lipoprotein-associated phospho-
lipase A2 (Lp-PLA2) is a member of the phospholipase
A2 family produced by inflammatory cells and mediates
vascular inflammation [14]. Elevated plasma Lp-PLA2
activity is positively correlated with an increase in in-
flammatory cytokines, particularly IL-6 [15]. A meta-
analysis of the prospective studies of Lp-PLA2 showed
an association between Lp-PLA2 activity and mass and a
worse prognosis of coronary artery disease (CAD), ische-
mic stroke, and vascular mortality [16]. In particular, a
higher level of Lp-PLA2 activity may imply a worse car-
diovascular prognosis in high-risk patients referred for
coronary angiography [17]. In addition to the effects that
fatty acid intake can have on the concentrations of lipids
and inflammatory markers, they may affect the level of
plasma C3 [14], which, itself, has been associated with
atherosclerosis and cardiovascular risk factors [18].
Research on the impacts of olive and canola oils on
cardiovascular biomarkers, particularly on inflammatory
biomarkers, is scarce. Therefore, the present study aimed
to examine the effects of CO and OO on plasma lipids,
inflammatory cytokines, Lp-PLA2 mass and activity, and




The participants were patients who referred for coronary
angiography to the Shahid Rajaei Cardiovascular, Med-
ical & Research Center, Tehran, Iran. Patients entered
the study 1 month after undergoing angiography to en-
sure that their medical and pharmacological status was
stable.
Eligible subjects were men and post-menopausal
women less than 75 years of age who had at least one
major cardiovascular risk factor, such as hypertension,
diabetes mellitus, dyslipidemia, or acute cardiac event.
The exclusion criteria were the regular use of anti-
inflammatory medication, dietary antioxidants, or
omega-3 supplements during the month prior to the
study; any changes in the disease treatment plan, includ-
ing type or dose of drugs or coronary artery bypass graft
(CABG); and gastrointestinal complications such as diar-
rhea during the study. In addition, participants with low
adherence to the intervention (who consumed less than
80% of the olive or canola oils delivered at baseline) were
excluded from the study.
Study design
The present study was a randomized, controlled, open-
label, parallel-arm clinical trial conducted in the spring
and summer of 2019 in Tehran, Iran. The enrollment
period ran from June 18, 2019 to September 15, 2019.
At baseline, demographic and medical information was
obtained through face-to-face interviews and reviews of
medical files, respectively. Cardiovascular risk factors
(hypertension, diabetes, and dyslipidemia) and past med-
ical histories were determined from the patients’ medical
records. All participants received dietary advice on a
heart-healthy diet at baseline. Daily consumption of at
least five servings of fruits and vegetables, substituting
lower-fat dairy products and meats for higher fats ones,
and lower use of salt and simple sugars were among the
dietary advice provided. Next, the participants were ran-
domly assigned to one of the two groups in a 1:1 ratio
following simple randomization procedures using
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computerized random numbers by one of the study re-
searchers not involved in patient care. Participants were
requested to consume a daily amount of 25 mL of re-
fined olive oil (OO) (Etka, Roodbar, Iran) or canola oil
(CO) (CanaPlus, British Columbia, Canada) raw with
meals for 6 weeks. The fatty acid composition of OO
and CO is shown in Table 1. Olive and canola oils were
provided to patients in sufficient quantities. To ensure
compliance with the intervention and proper oil con-
sumption, participants were followed up weekly by tele-
phone contact. If a participant consumed the
recommended amount of oil (25 ml per day) less than 5
days a week, s/he was excluded from the study.
The procedures followed in this trial were in accordance
with the 1964 Helsinki Declaration, and the study protocol
was approved by the Ethics Committee of the National
Nutrition & Food Technology Research Institute, Tehran,
Iran (No. IR.SBMU.NNFTRI.REC.1398.074). Written in-
formed consent was obtained from all participants prior
to beginning the study. This clinical trial was registered at
the Iranian Registry Center of Clinical Trials (IRCT)
(registration number: 20160702028742N5).
Anthropometric measures
Participant weight and height were measured at baseline
and after 6 weeks of intervention by the study dietitian.
Weight was measured without shoes, coats, or jackets
using a digital scale. Height was measured without shoes
using a wall-mounted stadiometer.
Biochemical parameters
Venous blood samples were obtained from each patient
after 12-h overnight fasting and collected into heparin-
ized tubes at baseline and after 6 weeks of intervention.
The blood samples were centrifuged (4000 rpm for 20
min), and the resulting plasma was stored at − 80 °C.
Plasma Lp-PLA2 mass and activity were analyzed by a
commercially available ELISA kit (ZellBio GmbH, Ulm,
Germany) and commercial colorimetric assay kit (Cay-
man Chemical, Ann Arbor, MI, USA), respectively. A
commercially available ELISA kit (Biolegend, San Diego,
CA, USA) was used to measure plasma IL-6
concentration. Plasma lipids and lipoproteins were ana-
lyzed using the colorimetry method with an auto-
analyzer (Selectra 2, Vital Scientific, Spankeren, The
Netherlands) using commercial kits (Pars Azmoon, Ka-
raj, Iran). Low-density lipoprotein-cholesterol (LDL-C)
was measured using a direct enzymatic method. The
small-dense LDL-cholesterol content in plasma was
quantitated according to the method described previ-
ously [19]. Non-high density lipoprotein-cholesterol
(Non-HDL-C) was calculated by subtracting HDL-C
from total cholesterol. Plasma levels of complement C3
and C4 were determined using the turbidimetric method
with commercial kits (Pars Azmoon, Karaj, Iran) using
an auto-analyzer.
Dietary intakes and physical activity
Dietary intake and physical activity levels were moni-
tored at baseline and after 6 weeks. Dietary intake was
assessed using the 24-h dietary recall questionnaire com-
pleted in 3 days (two regular days in the middle of the
week and 1 day on the weekend) by a trained dietitian.
Participants were asked to maintain their habitual life-
style throughout the study. Recall data was analyzed
using the Nutritionist software (version IV, N-Squared
Computing, San Bruno, CA, USA) to which was added
the local food data.
Statistical analysis
Although the primary outcome was Lp-PLA2, sample
size could not be calculated based on this variable, be-
cause according to our search, no study has compared
the effects of CO and OO on Lp-PLA2 mass or activity.
Nonetheless, studies have shown that Lp-PLA2 trans-
ported in plasma is predominantly (80%) associated with
LDL-C [20]. Therefore, the study sample size was calcu-
lated using LDL-C as the primary outcome variable. To
detect a change in the mean of LDL-C concentration
(10 mg/dL) as reported in a previous investigation [21]
at the 5% level of significance and with 80% power, 24
participants were needed in each arm of the two-arm
trial.
Data was analyzed using SPSS software for Windows
version 21 (SPSS Inc., Chicago, IL, USA). All values were
reported as mean ± SD or percentage (%). The per-
protocol analysis was performed (i.e., only those who
completed the study were included in the analyses). The
normality of distribution of the study variables was
tested by the Shapiro-Wilk test. When the variables were
not normally distributed, raw values were log-
transformed. Analysis of covariance (ANCOVA) was
used to compare the 6-week values between the groups
using the baseline measures as the covariate. Paired sam-
ples t-test was used to compare the measurements in
the beginning and at the end of the intervention within
Table 1 Chemical composition of oils
Chemical Component Canola Oil Refined Olive Oil
Fatty Acid (per 100 g):
Total SFAs 6.40 17.87
Total MUFA 61.37 66.68
Oleic acid 59.36 65.70
Total PUFAs 29.20 11.75
Linoleic acid 20.26 11.23
Alpha-linolenic acid 8.48 0.48
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the study groups. The χ2 test was used to compare cat-
egorical variables. The statistical significance level was
set at p = 0.05 (two tails).
Results
A total of 100 patients were screened for eligibility, and
48 patients entered the study. Six patients were excluded
during the intervention due to low adherence to dietary
intervention, travel, and refusal to continue. Therefore,
the final study population comprised 42 subjects: 22
subjects in the OO group, and 20 subjects in the CO
group (Fig. 1). Table 2 summarizes the general charac-
teristics of the participants. No significant differences
were observed in baseline characteristics between the
two groups.
Baseline levels and 6-week changes in anthropometric
measures are shown in Table 3. There were no signifi-
cant differences between the OO and CO groups con-
cerning body weight or physical activity at baseline and
after intervention.
As shown in Table 4, energy and dietary intakes of
nutrients did not differ between the groups at base-
line. Dietary intakes of total fat and monounsaturated
fat in both groups increased during the intervention
due to the consumption of olive and canola oils.
However, there were no differences in the dietary in-
takes of the two groups at 6 weeks after intervention.
Plasma levels of lipids, lipoproteins, and inflammatory
markers are shown in Table 5. The baseline values were
not different between the two groups. CO consumption
resulted in a significant reduction in plasma Lp-PLA2
mass (p = 0.008, power = 0.78) during the 6 weeks,
whereas the mean changes of IL-6 concentration were
significantly lower after OO consumption compared
with CO consumption (p = 0.008, power = 0.80). After 6
weeks of intervention, plasma Lp-PLA2 activity, C3, C4,
and lipid profiles had no significant changes in either
group (Table 5). Owing to some loss to follow-up, the
statistical power to detect differences in LDL-C was de-
creased (the actual power of test analysis was 0.70).
Discussion
The present study suggests that a relatively short diet-
ary intervention with refined olive oil can have a sig-
nificant effect on plasma IL-6 concentration. In
contrast, canola oil may impact plasma Lp-PLA2 mass
without changing lipoproteins or other inflammatory
biomarkers in patients referring for coronary angiog-
raphy (Fig. 2).
In the present study, the consumption of olive oil
had a greater lowering effect on plasma IL-6 concen-
tration. The difference in plasma IL-6 levels between
the two groups can be related to the difference in
fatty acid composition of canola and olive oils. In
Fig. 1 Consort flow diagram of selection and allocation of the participants included in the study
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particular, olive oil consists of 14.5% SFA, 70% oleic
acid, 11% linoleic acid, and 1.5% palmitoleic acid,
whereas canola oil is characterized by a low level of
SFAs (7%); 61% oleic acid, 19% linoleic acid, and 9%
alpha-linolenic acid (ALA) [22]. Compared to canola
oil, the amount of oleic and palmitoleic acid in olive
oil is higher. In vitro studies have shown that the
addition of oleic or palmitoleic acid to the cell culture
medium is effective in reducing or preventing in-
creases in IL-6 levels [23–26]. Some human studies
have shown evidence of an inverse association be-
tween oleic acid and IL-6 concentration [27]. In
addition, a diet rich in MUFA may also lower throm-
botic factors, including the von Willebrand factor
[28], the plasma levels of which are increased in high
risk populations [29], and its release may be induced
by IL-6 [30].
A growing body of evidence indicates that Lp-PLA2
represents an independent risk factor for CVD. Lp-PLA2
belongs to the family of structurally diverse phospholip-
ase A2 enzymes also known as platelet-activating factor
acetylhydrolase (PAF-AH) [31]. Circulating Lp-PLA2 is
primarily associated with LDL-C; the majority of it is
bound to atherogenic small-dense LDL-C particles [32].
In the present study, the consumption of CO-reduced
plasma Lp-PLA2 mass but not of its activity. Previous
studies have shown a modest correlation between Lp-
PLA2 mass and activity (30, 31). It has been suggested
Table 2 Baseline characteristics of the participants a
Variable Olive Oil group (n = 22) Canola Oil group (n = 20) P-value b
Age (year) 55.09 ± 6.92 59.30 ± 5.84 0.44
Sex (Male) 20 (91%) 18 (90%) 0.66
PCI history 16 (73%) 16 (80%) 0.89
CABG history 2 (9.1%) 1 (5%) 0.86
Diabetes Mellitus 8 (36%) 8 (40%) 0.91
Hypertension 11 (50%) 11 (55%) 0.92
Dyslipidemia 12 (54%) 8 (40%) 0.55
Overweight 16 (73%) 11 (55%) 0.19
Smoking 8 (36%) 4 (20%) 0.30
Medications:
Aspirin 21 (95%) 20 (100%) 0.93
Clopidogrel 15 (68%) 10 (50%) 0.29
Statins 20 (91%) 19 (95%) 0.93
ACEI 9 (41%) 4 (20%) 0.12
ARB 10 (45%) 13 (65%) 0.42
BB 15 (68%) 15 (75%) 0.81
Nitrates 7 (31%) 7 (35%) 0.90
Aldosteron Antagonist 5 (22%) 1 (5%) 0.17
aData presentedas Mean ± SD or number (percentage)
bData were compared using Independent t-testor Chi-square test
PCI Percutaneous Coronary Intervention, CABG Coronary Artery Bypass Graft, ACEI Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin Receptor Blocker,
BB Beta-Blocker
Table 3 Anthropometric measures and physical activity of the participantsa
Variable Time Olive Oil group (n = 22) Canola Oil group (n = 20) P-valueb
Body Weight (kg) Baseline 80.45 ± 11.77 78.65 ± 12.81 0.62
6-week 80.45 ± 11.49 78.30 ± 12.47 0.64
BMI (kg/m2) Baseline 26.91 ± 3.38 27.31 ± 4.39 0.34
6-week 26.94 ± 3.35 27.19 ± 4.31 0.30
Physical Activity (MET-h/day) Baseline 27.99 ± 5.23 27.30 ± 3.49 0.65
6-week 28.01 ± 5.23 27.36 ± 3.57 0.69
aAll values are Mean ± SD
bData were compared using Independent t-test
BMI Body Mass Index, MET Metabolic Equivalent
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that Lp-PLA2 is associated with LDL-C in plasma, and
this may result in the under-detection of Lp-PLA2 mass
by the ELISA method (32). However, all study samples
were measured in the same way in the current study,
thus possible under-detection of the Lp-PLA2 mass was
the same for the baseline and the final samples. Despite
this, both Lp-PLA2 mass and activity are predictors of
CVD events (33, 34). It has been shown that tocopherols
could inhibit Lp-PLA2 activity [33]. The amount of
alpha-tocopherol found in olive and canola oils is
similar; however, canola oil is richer in gamma-
tocopherol [34], which may influence the observed effect
on Lp-PLA2. The observed decrease in Lp-PLA2 levels
following CO consumption may also be related to its n-
3 fatty acid content. Canola oil contains more PUFAs
(both n-6 and n-3) and less MUFA than olive oil. In pa-
tients admitted to elective coronary angiography, the
content of long-chain n-3 PUFA eicosapentaenoic acid
(EPA) in adipose tissue was inversely associated with
plasma Lp-PLA2 mass [35]. Similarly, in participants of
Table 4 Dietary intake of the participants at the baseline and after the intervention a
Variable Time Olive Oil groupb (n = 22) Canola Oilgroupb (n = 20) P-value c
Energy (kcal) Baseline 1781.40 ± 196.10 1767.20 ± 146.19 0.55
6-week 1850.72 ± 143.20 1801.20 ± 140.44 0.26
Carbohydrate (g) Baseline 233.05 ± 32.18 235.20 ± 28.75 0.82
6-week 234.25 ± 33.57 232.85 ± 29.33 0.73
Carbohydrate (%) Baseline 51.90 ± 4.60 53.26 ± 5.16 0.38
6-week 50.47 ± 4.20 51.24 ± 4.97 0.60
Protein (g) Baseline 69.75 ± 15.55 74.25 ± 15.12 0.36
6-week 70.65 ± 11.27 73.30 ± 11.47 0.46
Protein (%) Baseline 15.51 ± 3.05 16.76 ± 2.84 0.18
6-week 15.29 ± 2.27 16.26 ± 2.05 0.16
Total Fat (g) Baseline 64.30 ± 11.59 59.05 ± 9.93 0.13
6-week 71.40 ± 7.91 † 68.90 ± 8.36† 0.33
Total Fat (%) Baseline 32.17 ± 4.53 30.05 ± 4.15 0.13
6-week 34.87 ± 4.36 † 34.47 ± 3.83† 0.75
SFA (g) Baseline 16.00 ± 4.56 16.10 ± 5.09 0.94
6-week 14.90 ± 3.56 13.75 ± 3.37 0.30
SFA (%) Baseline 7.99 ± 2.01 8.15 ± 2.24 0.82
6-week 7.28 ± 1.85 6.84 ± 1.44 0.40
MUFA (g) Baseline 19.45 ± 6.73 18.45 ± 4.09 0.26
6-week 30.30 ± 4.37 † 28.50 ± 3.53† 0.18
MUFA (%) Baseline 11.18 ± 2.99 10.38 ± 1.90 0.12
6-week 14.79 ± 2.45 † 14.25 ± 1.59† 0.10
PUFA (g) Baseline 25.10 ± 6.48 22.45 ± 4.11 0.13
6-week 23.75 ± 4.65 24.40 ± 2.76 0.59
PUFA (%) Baseline 12.58 ± 3.03 11.47 ± 2.21 0.19
6-week 11.56 ± 2.16 12.22 ± 1.37 0.25
Omega-3 (mg) Baseline 213.30 ± 178.73 167.25 ± 92.56 0.31
6-week 233.85 ± 150.65 221.55 ± 66.09† 0.27
Cholesterol (mg) Baseline 167.65 ± 82.15 170.00 ± 55.65 0.91
6-week 157.00 ± 73.63 167.35 ± 60.39 0.63
Fiber (g) Baseline 15.45 ± 2.32 14.60 ± 3.78 0.88
6-week 15.90 ± 2.78 15.75 ± 3.24 0.87
aAll values are Mean ± SD
b The daily olive or canola oil consumption is considered
cData were compared using Independent t-test
†Significantly different from Baseline. Data were compared using Paired t-test
SFA Saturated Fatty Acid, MUFA Monounsaturated Fatty Acids, PUFA Polyunsaturated Fatty Acids
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Table 5 Measures of biochemical variables by intervention groups a
Variable Olive Oil group (n = 22) Canola Oil group (n = 20) P c
Baseline 6-Week Δ value b Baseline 6-Week Δ value b
TC (mg/dL) 116.77 ± 25.15 124.36 ± 28.94 8.45 ± 17.67 136.25 ± 46.45 133.35 ± 47.54 −2.90 ± 16.81 0.10
LDL-C (mg/dL) 63.64 ± 13.72 67.36 ± 17.39 3.68 ± 11.27 74.65 ± 30.46 72.90 ± 28.98 −1.75 ± 9.03 0.16
sd-LDL (mg/dL) 24.14 ± 10.32 23.14 ± 11.18 −0.91 ± 6.34 22.10 ± 7.51 21.00 ± 9.48 − 1.10 ± 6.35 0.62
HDL-C (mg/dL) 37.73 ± 7.92 39.50 ± 7.46 1.50 ± 5.80 42.90 ± 6.49 43.15 ± 8.33 0.35 ± 5.21 0.79
TC/HDL-C 3.17 ± 0.47 3.25 ± 0.71 0.08 ± 0.39 3.06 ± 0.72 3.10 ± 0.83 0.03 ± 0.33 0.81
TG (mg/dL) 112.73 ± 33.04 120.50 ± 61.38 7.63 ± 36.45 122.45 ± 31.94 126.05 ± 35.40 3.90 ± 20.92 0.32
Lp-PLA2 mass
(ng/mL)
5.66 ± 4.09 6.00 ± 4.51 0.34 ± 1.57 3.96 ± 2.45 2.99 ± 1.65 − 0.97 ± 1.84 † 0.008
Lp-PLA2 Activity (nmol/min/mL) 0.022 ± 0.013 0.021 ± 0.017 − 0.000 ± 0.008 0.012 ± 0.003 0.010 ± 0.004 − 0.001 ± 0.002 0.74
IL-6 (pg/mL) 21.95 ± 20.38 12.49 ± 13.70 − 9.46 ± 9.46 † 19.53 ± 10.52 18.62 ± 8.55 −0.90 ± 6.80 0.008
C3 (g/L) 199.32 ± 35.04 200.68 ± 33.63 1.36 ± 36.64 205.30 ± 44.46 223.50 ± 42.40 18.10 ± 49.00 0.08
C4 (g/L) 38.82 ± 11.99 36.23 ± 9.48 −2.59 ± 9.09 39.20 ± 9.03 34.60 ± 10.35 −4.55 ± 12.43 0.52
C3/C4 5.56 ± 1.98 5.37 ± 2.08 0.23 ± 0.91 5.37 ± 2.08 6.36 ± 2.45 0.99 ± 2.53 0.27
a All values are Mean ± SD
b Change of parameter between 6-week and baseline (6-week minus baseline)
c The values for 6-week were analyzed using ANCOVA with baseline values as covariate
† Significantly different from baseline. Data were compared using Paired t-test
TC Total Cholesterol, LDL-C Low Density Lipoprotein-Cholesterol, sd-LDL Small Dense LDL, HDL High Density Lipoprotein-Cholesterol, TG Triglyceride, Lp-PLA2
Lipoprotein-Associated Phospholipase A2, IL-6 Interleukin-6, C3 Complement component 3, C4 Complement component 4
Fig. 2 Summary of research rationale and main findings
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the Multi-Ethnic Study of Atherosclerosis, plasma Lp-
PLA2 mass and activity were significantly lower in those
with higher plasma EPA and docosahexaenoic acid
(DHA) levels [36]. The evidence from intervention trials
examining the influence of n-3 PUFAs on Lp-PLA2 is
ambiguous. In healthy people, two studies have reported
no effect of n-3 PUFA supplementation on Lp-PLA2 [37,
38]. Nelson et al. showed that supplementation with n-3
fatty acid capsules (fish oil or flaxseed oil) over 8 weeks
had no significant effect on plasma Lp-PLA2 mass or ac-
tivity when compared to the control (olive oil capsule
supplementation) [37]. In contrast, Asztalos et al.
showed that compared to the placebo (6 g/day olive oil),
supplementation with the higher dose of EPA (1800 mg)
but not DHA or a lower dose of EPA (600 mg) over 6
weeks can reduce Lp-PLA2 mass in a healthy population
[39]. Apart from the effects in healthy subjects, an in-
crease in n-3 intake has been shown to decrease Lp-
PLA2 levels in patients with cardiovascular risk factors.
In stable CAD patients undergoing percutaneous coron-
ary intervention, the administration of omega-3 PUFA
(1 g/day) for 4 weeks decreased Lp-PLA2 mass and activ-
ity compared to the control (soybean oil capsules) [40].
Similar findings have been observed in patients with dia-
betes [41] and subjects who had residual hypertriglyc-
eridemia after receiving statins [42, 43].
The pro-atherogenic role of Lp-PLA2 could be related
to its ability to hydrolyze oxidized phospholipids on the
LDL-C surface, resulting in the generation of two proin-
flammatory and pro-apoptotic lipid mediators, lysopho-
sphatidylcholine, and oxidized free fatty acids, which
play an important role in the development of athero-
sclerotic necrotic cores by recruiting and activating mac-
rophages or leukocytes [44]. In the present study,
although canola oil reduced Lp-PLA2 levels, it had no
significant effect on inflammatory factors. Consistent
with this result, supplementation with n-3 fatty acids
(EPA) reduced plasma Lp-PLA2 without having a signifi-
cant effect on plasma inflammatory biomarkers, includ-
ing IL-6 [39].
Complement factors C3 and C4 have been associ-
ated with atherosclerosis and cardiovascular risk fac-
tors [18] and have shown substantial correlations with
cardiovascular risk factors [45]. Plasma C3 and C4
did not change in either group. In a previous study,
an increase was observed in C3 concentration after
the intake of high saturated fat compared with high-
monounsaturated fat [14].
In the current study, neither olive oil nor canola oil
consumption had a significant impact on plasma lipids
or lipoproteins. Consistent with these findings, previous
studies have reported no significant effect of the intake
of refined OO (60 g/day) on plasma TG, LDL-C, or
HDL-C levels in mildly hypercholesterolemic subjects
who were not on lipid-lowering medications [46] or in
stable coronary artery disease patients (50 mL/day) [47].
However, some previous studies have reported the bene-
ficial effects of CO on plasma lipids [48–51]. Neverthe-
less, it should be noted that the study population in
these studies were healthy people or those with cardio-
vascular risk factors who were not taking lipid-lowering
agents. In contrast, most of the participants in the
present study were under statin therapy and had an
optimum level of plasma lipids. Therefore, the beneficial
effects of canola oil on plasma lipid profiles appear to be
evident in patients whose plasma lipids are high at base-
line and are not on lipid-lowering medication. CO or
OO intake in the context of a lipid-lowering diet for 3.5
weeks in hyperlipidemic subjects who were not on lipid-
lowering agents had similar effects on serum lipoprotein
concentration [22].
Study strengths and limitations
The comparison of two commonly consumed edible
oils and the detailed data collection were strengths of
the current study; however, the present study also
had some limitations. The study had no run-in
period. Since participants received dietary advice on a
heart-healthy diet at baseline, effects due to changes
in dietary habits could not be excluded, and part of
the observed effects on investigated biomarkers may
be related to dietary habits modification. Participants
of both groups received similar dietary advice, how-
ever, and the potential effects were present in both
groups. The duration of dietary intervention was rela-
tively short. Furthermore, some participants were lost
to follow-up and/or discontinued the intervention,
which reduced the final sample size. In addition, we
were unable to blind the participants because of the
sensory and appearance characteristics of the two oils.
Moreover, the study could not be conducted in a
tightly regulated, controlled feeding design. The study
oils were provided to individuals (more than each
participant’s need), and their consumption was moni-
tored weekly. Because most participants were male,
the sample cannot be considered representative, and
this may limit the findings to a specific sex. Further-
more, the cross-over study design could have reduced
the confounding factors associated with the inherited
characteristics of the participants. Nevertheless, cross-
over studies require that study participants be
followed for a more extended period and that their
treatment plan should not change during this time.
Moreover, given that most of the population spends
most of their time in the postprandial state, measure-
ments of postprandial lipids and inflammatory
markers could have provided additional information
on potential changes in cardiovascular risk.
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Conclusions
In summary, each of the refined olive or canola oils
improved one of the inflammatory CVD risk factors.
Comparing the two vegetable oils in subjects with car-
diovascular risk factors showed that the consumption of
olive oil is more effective in reducing the level of inflam-
matory cytokine IL-6, whereas canola oil is more effect-
ive in lowering the level of LP-PLA2. Regarding the role
of the circulating level of IL-6 in predicting future cor-
onary heart disease events [52–54], a decrease in IL-6
level following olive oil consumption can reduce the risk
of cardiovascular events. On the other hand, canola oil
consumption decreased the level of Lp-PLA2, the in-
creased levels of which have been associated with in-
creased risk of cardiovascular events [16]. This finding
should be interpreted with caution, however, because
the Lp-PLA2 activity did not change significantly. Over-
all, the consumption of either refined olive or canola oils
in the context of a healthy diet may have a beneficial ef-
fect on the secondary prevention of CVD by improving
inflammatory risk factors.
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